IOL Chemicals and Pharmaceuticals (IOLCP) has received from US Food and Drug Administration (USFDA), Establishment Inspection Report after successful inspection of its Ibuprofen manufacturing facility situated at Barnala, Punjab, India.
Post this approval, the company will be able to garner additional business for its flagship API Ibuprofen in World's largest pharma market-USA. This will result into higher value added export turnover and higher margins.
The company’s manufacturing facility already holds CEP certification (Certificate of Suitability) for its products Ibuprofen, Metformin Hydrochloride & Lamotrigine from European Directorate for the Quality of Medicines & HealthCare (EDQM) authorities, Council of Europe, France. The said facility at Barnala has also been approved by ANVISA Brazil, WHO & MOH Japan.
These approvals will help the company to build and sustaining the growth by its API business in coming years, being the only integrated player globally, by exploring the higher value added regulated markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: